Showing results (391-400 of 428) with videos related to
Sort By:
Pageof 43
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 24, 2017
Fractionated Radiation Therapy Stimulates Antitumor Immunity Mediated by Both Resident and Infiltrating Polyclonal T-cell Populations when Combined with PD-1 BlockadeSimon J Dovedi, Eleanor J Cheadle, Amy L Popple, et al.Alzheimer'S Research & Therapy|July 5, 2017
Cerebrospinal fluid biomarkers for Alzheimer's and vascular disease vary by age, gender, and APOE genotype in cognitively normal adultsGe Li, Jane B Shofer, Eric C Petrie, et al.Bioorganic & Medicinal Chemistry Letters|February 26, 2008
Synthesis and SAR of 1-acetanilide-4-aminopyrazole-substituted quinazolines: selective inhibitors of Aurora B kinase with potent anti-tumor activityKevin M Foote, Andrew A Mortlock, Nicola M Heron, et al.The Journal of Clinical Investigation|January 31, 2017
A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancerChiara Berlato, Moddasar N Khan, Tiziana Schioppa, et al.Neurobiology of Disease|June 17, 2017
Blast-related disinhibition and risk seeking in mice and combat Veterans: Potential role for dysfunctional phasic dopamine releaseA G Schindler, J S Meabon, K F Pagulayan, et al.JAMA Neurology|June 20, 2013
Effect of apolipoprotein E genotype and diet on apolipoprotein E lipidation and amyloid peptides: randomized clinical trialAngela J Hanson, Jennifer L Bayer-Carter, Pattie S Green, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2023
A B7-H4-Targeting Antibody-Drug Conjugate Shows Antitumor Activity in PARPi and Platinum-Resistant Cancers with B7-H4 ExpressionSarah B Gitto, Margaret Whicker, Gareth Davies, et al.Journal for Immunotherapy of Cancer|August 16, 2017
The MEK inhibitor selumetinib complements CTLA-4 blockade by reprogramming the tumor immune microenvironmentEdmund Poon, Stefanie Mullins, Amanda Watkins, et al.Molecular Cancer Therapeutics|July 5, 2021
Recombinant Newcastle Disease Virus Immunotherapy Drives Oncolytic Effects and Durable Systemic Antitumor ImmunityJames Harper, Shannon Burke, Jon Travers, et al.Nature Plants|January 5, 2023
Long-lasting memory of jasmonic acid-dependent immunity requires DNA demethylation and ARGONAUTE1S W Wilkinson, A Hannan Parker, A Muench, et al.Pageof 43